Kiniksa Pharmaceuticals International, plc
KNSADrugs in Pipeline
8
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How KNSA's past catalysts played out
Rilonacept
Recurrent Pericarditis
mavrilimumab
COVID
KPL-387
Pericarditis
Vixarelimab
Prurigo Nodularis
KPL-716
Chronic Idiopathic Urticaria
prednisone
Giant Cell Arteritis
KPL-404
Arthritis, Rheumatoid
KPL-914
Recurrent Pericarditis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rilonacept | Phase 3 | Recurrent Pericarditis | - | - |
mavrilimumab | Phase 3 | COVID | - | - |
KPL-387 | Phase 3 | Pericarditis | - | - |
Vixarelimab | Phase 2 | Prurigo Nodularis | - | - |
KPL-716 | Phase 2 | Chronic Idiopathic Urticaria | - | - |
prednisone | Phase 2 | Giant Cell Arteritis | - | - |
KPL-404 | Phase 2 | Arthritis, Rheumatoid | - | - |
KPL-914 | Phase 2 | Recurrent Pericarditis | - | - |
Frequently asked questions
What is in Kiniksa Pharmaceuticals International, plc's drug pipeline?→
CatalystAlert tracks 8 drug candidates in Kiniksa Pharmaceuticals International, plc's (KNSA) pipeline across Phase 3, Phase 2. Its lead program is Rilonacept (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kiniksa Pharmaceuticals International, plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Kiniksa Pharmaceuticals International, plc (KNSA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KNSA biotech catalysts?→
Add KNSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kiniksa Pharmaceuticals International, plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.